09 jun: Berkshire Sells Unsecured ResCap Bonds
09 jun: Thousands Of AT&T Employees In Calif., Nevada Hold Walkou..
09-06-2012 00:07:00

UPDATE: J&J to Record $600 Million Charge Due to Outstanding Lawsuits

Relateret indhold
Relateret debat
13:54 - 
We are direct provider for BG/SBLC specifically for lea..
01 sep - 
Dear Sir/Ma, We have direct providers of Fresh Cut BG, ..
01 sep - 
We are direct provider for BG/SBLC specifically for lea..

--J&J to take litigation charge of about $600 million in second quarter

--Charge deals with litigation surrounding drugs Risperdal, Invega and Natrecor

--Took $1.1 billion litigation charge in the fourth quarter of 2011

(Updated to include details of previous litigation charge in the third paragraph.)

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

In the fourth quarter, J&J recorded a $1.1 billion charge related to litigation settlements. At the time, Chief Financial Officer Dominic Caruso said the litigation costs were primarily linked to Risperdal. The company didn't have a similar charge in its April first-quarter report.

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

J&J also has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

--Anjali Athavaley contributed to this report.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 18:07 ET (22:07 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Spar Nord vil ikke købe kunder fra FS

02-10-2014 14:25:02
Det bliver ikke Spar Nord, der køber den udbudte kundeportefølje fra Finansiel Stabilitet.Det siger talsmand for Spar Nord Ole Madsen til Bloomberg News.Spar No..

Aktier/åbning: B&O bankes baglæns i negativt marked

02-10-2014 09:19:33
Selvom fjerde kvartal normalt er aktieårets bedste, så startede kvartalet ikke godt. På kvartalets første handelsdag onsdag faldt aktierne, og det er også tilfæ..

Aktier/tendens: Fortsat usikkerhed kan presse markedet

02-10-2014 08:38:41
Selvom fjerde kvartal normalt er aktieårets bedste, så tyder starten indtil videre ikke på det. På kvartalets første handelsdag onsdag faldt aktierne, og det te..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Danske aktier rammes af flersidet nedtur
2
ECB/Danske: Klart signal fra Draghi
3
B&O får hvinende kurslussing efter skuffende regnskab - NY
4
Aktier/tendens: Fortsat usikkerhed kan presse markedet
5
B&O Q1: Underskuddet forværres - forventninger præciseres opad

Relaterede aktiekurser

Johnson & Johnson 103,81 -0,5% Fald i aktiekurs
Omnicare Inc 60,73 -1,0% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
2. oktober 2014 18:31:16
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141002.2 - EUROWEB1 - 2014-10-02 18:31:16 - 2014-10-02 18:31:16 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x